This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Prakash C. Deedwania, MD; Enrique V. Carbajal, MD
Fresno, Calif

Arch Intern Med. 1993;153(19):2281-2287.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We agree with the comment of Hansen that the findings of the Secondary Prevention Reinfarction Israel Nifedipine Trial¹ clearly emphasize the importance of differences in the actions of various calcium-channel blockers. As stated by Hansen, the results of the Second Danish Verapamil Infarction Trial II² were in clear contrast with the findings reported by the Israel trial investigators. Although early administration of nifedipine in survivors of acute myocardial infarction (in the Danish trial) was associated with increased mortality in the postinfarction period, the results of the Danish trial demonstrated a beneficial effect of verapamil in reducing the risk of reinfarction in the postinfarction period. Although there were some differences in the clinical features and the initiation of therapy with the specific calcium-channel blocker in the two studies, it is unlikely that these differences account for the contrasting results. As described previously,³ the most likely explanation for the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?